BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31118564)

  • 1. Antileishmanial and antitrypanosomal activity of symmetrical dibenzyl-substituted α,β-unsaturated carbonyl-based compounds.
    Alkhaldi AA; de Koning HP; Bukhari SNA
    Drug Des Devel Ther; 2019; 13():1179-1185. PubMed ID: 31118564
    [No Abstract]   [Full Text] [Related]  

  • 2. Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
    Cogo J; Cantizani J; Cotillo I; Sangi DP; Corrêa AG; Ueda-Nakamura T; Filho BPD; Martín JJ; Nakamura CV
    Bioorg Med Chem; 2018 Aug; 26(14):4065-4072. PubMed ID: 30100019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
    Manda S; Khan SI; Jain SK; Mohammed S; Tekwani BL; Khan IA; Vishwakarma RA; Bharate SB
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3247-50. PubMed ID: 24980054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives.
    Castillo E; Dea-Ayuela MA; Bolás-Fernández F; Rangel M; González-Rosende ME
    Curr Med Chem; 2010; 17(33):4027-51. PubMed ID: 20939823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of arylsubstituted imidazoles derivatives as antiprotozoal agents and docking studies on sterol 14α-demethylase (CYP51) from Trypanosoma cruzi, Leishmania infantum, and Trypanosoma brucei.
    Rojas Vargas JA; López AG; Pérez Y; Cos P; Froeyen M
    Parasitol Res; 2019 May; 118(5):1533-1548. PubMed ID: 30903349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases.
    Kourbeli V; Chontzopoulou E; Moschovou K; Pavlos D; Mavromoustakos T; Papanastasiou IP
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of Sulfonamide Derivatives in the Treatment of Trypanosomatid Parasites including Trypanosoma cruzi, Trypanosoma brucei, and Leishmania ssp.
    Scarim CB; Chelucci RC; Dos Santos JL; Chin CM
    Med Chem; 2020; 16(1):24-38. PubMed ID: 31218962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavonoid-derived Privileged Scaffolds in anti-Trypanosoma brucei Drug Discovery.
    Boniface PK; Elizabeth FI
    Curr Drug Targets; 2019; 20(12):1295-1314. PubMed ID: 31215385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
    Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
    J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antiprotozoal activity of a novel semi-synthetic berberine derivative.
    Bahar M; Deng Y; Zhu X; He S; Pandharkar T; Drew ME; Navarro-Vázquez A; Anklin C; Gil RR; Doskotch RW; Werbovetz KA; Kinghorn AD
    Bioorg Med Chem Lett; 2011 May; 21(9):2606-10. PubMed ID: 21474310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anilinoquinoline based inhibitors of trypanosomatid proliferation.
    Ferrins L; Sharma A; Thomas SM; Mehta N; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Gillingwater K; Pollastri MP
    PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006834. PubMed ID: 30475800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Substituted 3-chlorokenpaullone derivatives are potent inhibitors of Trypanosoma brucei bloodstream forms.
    Orban OC; Korn RS; Benítez D; Medeiros A; Preu L; Loaëc N; Meijer L; Koch O; Comini MA; Kunick C
    Bioorg Med Chem; 2016 Aug; 24(16):3790-800. PubMed ID: 27349574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parasitology. Drugs to combat tropical protozoan parasites.
    Gelb MH; Hol WG
    Science; 2002 Jul; 297(5580):343-4. PubMed ID: 12130767
    [No Abstract]   [Full Text] [Related]  

  • 14. Design and synthesis of N-(3-sulfamoylphenyl)amides as Trypanosoma brucei leucyl-tRNA synthetase inhibitors.
    Li Z; Xin W; Wang Q; Zhu M; Zhou H
    Eur J Med Chem; 2021 May; 217():113319. PubMed ID: 33725631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
    Abdeen S; Salim N; Mammadova N; Summers CM; Goldsmith-Pestana K; McMahon-Pratt D; Schultz PG; Horwich AL; Chapman E; Johnson SM
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5247-5253. PubMed ID: 27720295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel 4-alkapolyenylpyrrolo[1,2-a]quinoxalines as antileishmanial agents--part III.
    Ronga L; Del Favero M; Cohen A; Soum C; Le Pape P; Savrimoutou S; Pinaud N; Mullié C; Daulouede S; Vincendeau P; Farvacques N; Agnamey P; Pagniez F; Hutter S; Azas N; Sonnet P; Guillon J
    Eur J Med Chem; 2014 Jun; 81():378-93. PubMed ID: 24858543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening a Natural Product-Based Library against Kinetoplastid Parasites.
    Zulfiqar B; Jones AJ; Sykes ML; Shelper TB; Davis RA; Avery VM
    Molecules; 2017 Oct; 22(10):. PubMed ID: 29023425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2,4-Diaminopyrimidines as potent inhibitors of Trypanosoma brucei and identification of molecular targets by a chemical proteomics approach.
    Mercer L; Bowling T; Perales J; Freeman J; Nguyen T; Bacchi C; Yarlett N; Don R; Jacobs R; Nare B
    PLoS Negl Trop Dis; 2011 Feb; 5(2):e956. PubMed ID: 21347454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents.
    Corfu AI; Santarem N; Luelmo S; Mazza G; Greco A; Altomare A; Ferrario G; Nasta G; Keminer O; Aldini G; Tamborini L; Basilico N; Parapini S; Gul S; Cordeiro-da-Silva A; Conti P; Borsari C
    ACS Infect Dis; 2024 Jun; 10(6):2222-2238. PubMed ID: 38717116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.
    Tulloch LB; Martini VP; Iulek J; Huggan JK; Lee JH; Gibson CL; Smith TK; Suckling CJ; Hunter WN
    J Med Chem; 2010 Jan; 53(1):221-9. PubMed ID: 19916554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.